help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, J. C.
Right arrow Articles by Naqvi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, J. C.
Right arrow Articles by Naqvi, T.
The Oncologist, Vol. 8, No. 4, 375–380, August 2003
© 2003 AlphaMed Press


ORIGINAL PAPER
Symptom Management and Supportive Care

Thrombotic Thrombocytopenic Purpura Associated with Bone Marrow Metastasis and Secondary Myelofibrosis in Cancer

Jae C. Changa, Tahir Naqvib

a University of California, Irvine College of Medicine and Division of Hematology/Oncology at UCI Medical Center, Orange, California, USA; b Department of Medicine, Wright State University School of Medicine, Dayton, Ohio, USA, and Hematology and Oncology Section, Good Samaritan Hospital, Dayton, Ohio, USA

Correspondence: Jae C. Chang, M.D., Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California at Irvine Medical Center, 101 The City Drive, Orange, California 92868, USA. Telephone: 714-456-5153; Fax 714-456-2242; e-mail: jaec{at}uci.edu

To examine the relationship between cancer and development of thrombotic microangiopathy (TM), the medical records of patients with known TM were examined in one institution from January 1981 to December 2002. Nine out of 93 patients with the established diagnosis of TM had active cancer. All nine of those patients had thrombotic thrombocytopenic purpura (TTP). Among those patients, two patients received chemotherapy prior to the development of TTP. Six of the seven patients who received no chemotherapy had extensive bone marrow metastasis and secondary myelofibrosis. There were two patients each with breast cancer, lung cancer, and stomach cancer. Severe anemia and thrombocytopenia with leukoerythroblastosis were prominent clinical features in all six patients. Four patients had neurological (mental) changes and three developed fever, but none had significant renal dysfunction. Upon establishing the diagnosis of TTP, four patients were treated with exchange plasmapheresis (EP) and two patients were treated with chemotherapy because there were no neurological changes. Three patients achieved complete remission of TTP, one with EP alone and two with chemotherapy. The one patient who achieved remission with EP alone was later treated with chemotherapy and survived for 2 1/2 years. The other three patients treated with EP alone died within 2 months after the diagnosis of TTP. Since TTP occurred in association with bone marrow metastasis and myelofibrosis in six patients among seven chemotherapy-untreated cancer patients, this marrow change was considered to be the possible cause of the development of TTP. It is recommended that all cancer patients with unexplained anemia and thrombocytopenia be evaluated for the coexistence of bone marrow metastasis and TTP.

Key Words. Thrombotic thrombocytopenic purpura • Bone marrow metastasis • Secondary myelofibrosis • Microangiopathic hemolytic anemia • Thrombotic microangiopathy




This article has been cited by other articles:


Home page
Ann OncolHome page
I. Spoormans, S. Altintas, J. Van den Brande, A. Luijks, and J. B. Vermorken
Purpura in a patient with disseminated breast cancer: a rapidly progressive cancer-related thrombotic thrombocytopenic purpura
Ann. Onc., June 1, 2008; 19(6): 1204 - 1207.
[Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
A. Sevinc, M. E. Kalender, Y. Pehlivan, I. Sari, and C. Camci
Thrombotic Thrombocytopenic Purpura and Bone Marrow Necrosis as the Initial Presentation of Lung Cancer
Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 449 - 452.
[Abstract] [PDF]


Home page
The OncologistHome page
M. T. Pirrotta, A. Bucalossi, F. Forconi, M. Bocchia, S. Mazzotta, S. Sammassimo, A. Gozzetti, and F. Lauria
Thrombotic Thrombocytopenic Purpura Secondary to an Occult Adenocarcinoma
Oncologist, April 1, 2005; 10(4): 299 - 300.
[Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
J.-L. Lee, J.-H. Lee, M.-K. Kim, H. S. Cho, Y. K. Bae, K. H. Cho, S. H. Bae, H. M. Ryoo, K. H. Lee, and M. S. Hyun
A Case of Bone Marrow Necrosis with Thrombotic Thrombocytopenic Purpura as a Manifestation of Occult Colon Cancer
Jpn. J. Clin. Oncol., August 1, 2004; 34(8): 476 - 480.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2003 by AlphaMed Press.